not tagged
not tagged
['breast']
presenting at #asco22, dana-farber's fengmin zhao, phd, leads research that shows #breastcancer patients with moderate to high treatment bother before starting an aromatase inhibitor were at a higher risk of stopping the treatment early.
read more: 
Your official source for @DanaFarber Cancer Institute news | Research, science, and innovation | Media requests: media@dfci.harvard.edu or 617-632-4090